Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer

被引：0
|
作者：
Qiu, H. [1 ]
Dai, Y. [1 ]
Huang, T. [1 ]
Sun, L. [1 ]
Zhuang, L. [1 ]
Zhang, M. [1 ]
Zou, Y. [1 ]
Yuan, X. [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.949
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
428P
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [21] Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study)
    Nakamura, Masato
    Yamada, Takeshi
    Ishiyama, Shun
    Enomoto, Masanobu
    Yokomizo, Hajime
    Kosugi, Chihiro
    Sonoda, Hiromichi
    Ishimaru, Kei
    Ishibashi, Keiichiro
    Kuramochi, Hidekazu
    Nozawa, Keijiro
    Ohta, Ryo
    Takahashi, Makoto
    Yoshida, Hiroshi
    Hashiguchi, Yojiro
    Hirata, Keiji
    Katsumata, Kenji
    Ishida, Hideyuki
    Koda, Keiji
    Sakamoto, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [22] Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study
    Li, Rong-Rong
    Yin, Xian-Li
    Zeng, De-Yu
    Shao, Feng-Jiang
    Yamamoto, Seiichiro
    Liu, Wu
    Liu, Zhen-Yang
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (16)
  • [23] Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
    Koizumi, W.
    Boku, N.
    Yamaguchi, K.
    Miyata, Y.
    Sawaki, A.
    Kato, T.
    Toh, Y.
    Hyodo, I.
    Nishina, T.
    Furuhata, T.
    Miyashita, K.
    Okada, Y.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 766 - 771
  • [24] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [25] Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer
    An, Tian-Qi
    Qiu, Hui
    Zhou, Quan-Bo
    Zong, Hong
    Hu, Shuang
    Lian, Yu-Gui
    Zhao, Rui-Hua
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (06) : 2449 - 2462
  • [26] FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
    Calegari, Maria Alessandra
    Zurlo, Ina Valeria
    Di Stefano, Brunella
    Camarda, Floriana
    Di Dio, Carmela
    Garufi, Giovanna
    Cassano, Alessandra
    Barone, Carlo Antonio
    Bria, Emilio
    Basso, Michele
    Orlandi, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [27] Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
    Chen Yue
    Xu Yu-ying
    Jiang Hai-jun
    Wang Lei
    Zhai Jia-wei
    Zhang Tong
    Yang Yu-fei
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2022, 28 (10) : 924 - 929
  • [28] Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
    Yue Chen
    Yu-ying Xu
    Hai-jun Jiang
    Lei Wang
    Jia-wei Zhai
    Tong Zhang
    Yu-fei Yang
    Chinese Journal of Integrative Medicine, 2022, 28 : 924 - 929
  • [29] Self-reported adherence to regorafenib for metastatic colorectal cancer: A retrospective cohort study.
    Kawakami, Kazuyoshi
    Suenaga, Mitsukuni
    Soejima, Azusa
    Sugita, Kazuo
    Yokokawa, Takashi
    Suzuki, Kenichi
    Inoue, Ayaka
    Machida, Yohiaki
    Wakatsuki, Takeru
    Yamaguchi, Kensei
    Hama, Toshihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [30] Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
    CHEN Yue
    XU Yu-ying
    JIANG Hai-jun
    WANG Lei
    ZHAI Jia-wei
    ZHANG Tong
    YANG Yu-fei
    Chinese Journal of Integrative Medicine, 2022, 28 (10) : 924 - 929
12345